Signal
GSK’s hepatitis B drug achieves functional cure in nearly one-fifth of patients in phase 3 trials
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-05-28 08:39 UTCUpdated 2026-05-28 16:01 UTC
rss
clinical_trialsdrug_developmentsafety_signals
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
GSK and Ionis Pharmaceuticals reported phase 3 trial results for bepirovirsen, showing nearly 20% of patients with chronic hepatitis B achieved a functional cure.
Entities
GSKIonis Pharmaceuticalsbepirovirsen
Score total
1.31
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
0%
Why now
- Phase 3 trial results have just been released, confirming efficacy in a large patient population.
- The data represent a major advancement in a field with few effective cures.
- GSK and Ionis are positioned to potentially bring a first-in-class hepatitis B cure to market.
Why it matters
- Hepatitis B affects millions globally with limited curative treatments.
- A functional cure could greatly reduce disease burden and improve outcomes.
- Positive phase 3 data may speed regulatory approval and treatment availability.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Bepirovirsen achieved functional cure in nearly 20% of patients in phase 3 trials.
How sources frame it
- BioPharma Dive: supportive
Consolidated multiple reports to highlight the clinical significance of bepirovirsen's phase 3 results.
All evidence
All evidence
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
BioPharma Dive · biopharmadive.com · 2026-05-28 16:01 UTC
GSK hails 'unprecedented' cure rates with hep B drug
pharmaphorum · pharmaphorum.com · 2026-05-28 11:55 UTC
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials we...
Fierce Biotech · fiercebiotech.com · 2026-05-28 08:39 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- pharmaphorum (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- pharmaphorum.com (1)
- fiercebiotech.com (1)